Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer

MT Newswires Live

Nov 14, 2024

Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated "significant improvement" in overall response rate.

The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.

Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.

Price: 2.08, Change: +0.21, Percent Change: +11.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483800643"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483800643\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483800643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483800643","market":"hk","top_or_hot":-1,"title":"Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer","media":"MT Newswires Live","content":"<html><body><p> Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.</p><p>The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated \"significant improvement\" in overall response rate.</p><p>The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.</p><p>Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.</p><p>Price: 2.08, Change: +0.21, Percent Change: +11.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-14 23:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.</p><p>The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated \"significant improvement\" in overall response rate.</p><p>The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.</p><p>Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.</p><p>Price: 2.08, Change: +0.21, Percent Change: +11.23</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMP","symbol_name":"Immutep Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483800643","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483800643","pubTimestamp":1731597969,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated \"significant improvement\" in overall response rate.The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.Price: 2.08, Change: +0.21, Percent Change: +11.23","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMMP":"Immutep Limited","BK4139":"生物科技"},"translate_title":"Efti联合疗法治疗非小细胞肺癌的1期试验数据积极后，Immutep股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMP":0.9},"content_text":"Immutep (IMMP) shares were up more than 11% in recent Thursday trading after the company reported positive data from the phase 1 trial evaluating eftilagimod alpha, also known as efti, in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.The company said the trial's overall survival and progression-free survival data, with a minimum follow-up of almost two years, exceeded expectations and all evaluable patients to date also demonstrated \"significant improvement\" in overall response rate.The combination therapy also continued to demonstrate a favorable safety profile, Immutep added.Immutep said the phase 1 trial is nearing the completion of its patient enrollment, with additional data updates expected in 2025.Price: 2.08, Change: +0.21, Percent Change: +11.23","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}